Your Good Partner in Biology Research

重組蛋白

產(chǎn)品名稱 貨號(hào) 規(guī)格
Recombinant Vibrio harveyi Ribosomal RNA large subunit methyltransferase L (rlmL), partial CSB-YP417774VEA
CSB-EP417774VEA
CSB-BP417774VEA
CSB-MP417774VEA
CSB-EP417774VEA-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Vibrio harveyi Membrane protein insertase YidC (yidC), partial CSB-YP417775VEA1
CSB-EP417775VEA1
CSB-BP417775VEA1
CSB-MP417775VEA1
CSB-EP417775VEA1-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Vibrio harveyi Phosphomethylpyrimidine synthase (thiC), partial CSB-YP417776VEA
CSB-EP417776VEA
CSB-BP417776VEA
CSB-MP417776VEA
CSB-EP417776VEA-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Vibrio harveyi Ribonuclease P protein component (rnpA) CSB-YP417777VEA
CSB-EP417777VEA
CSB-BP417777VEA
CSB-MP417777VEA
CSB-EP417777VEA-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Vibrio harveyi Holliday junction ATP-dependent DNA helicase RuvB (ruvB) CSB-YP417778VEA
CSB-EP417778VEA
CSB-BP417778VEA
CSB-MP417778VEA
CSB-EP417778VEA-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Vibrio harveyi ATP-dependent Clp protease adapter protein ClpS (clpS) CSB-YP417779VEA
CSB-EP417779VEA
CSB-BP417779VEA
CSB-MP417779VEA
CSB-EP417779VEA-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Vibrio harveyi Ribosomal RNA large subunit methyltransferase G (rlmG) CSB-YP417780VEA
CSB-EP417780VEA
CSB-BP417780VEA
CSB-MP417780VEA
CSB-EP417780VEA-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Vibrio harveyi Protoheme IX farnesyltransferase 1 (cyoE1), partial CSB-YP417781VEA
CSB-EP417781VEA
CSB-BP417781VEA
CSB-MP417781VEA
CSB-EP417781VEA-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Vibrio harveyi Probable phosphatase VIBHAR_04983 (VIBHAR_04983) CSB-YP417782VEA
CSB-EP417782VEA
CSB-BP417782VEA
CSB-MP417782VEA
CSB-EP417782VEA-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Vibrio harveyi Acetyl-coenzyme A carboxylase carboxyl transferase subunit beta 2 (accD2) CSB-YP417783VEA
CSB-EP417783VEA
CSB-BP417783VEA
CSB-MP417783VEA
CSB-EP417783VEA-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Vibrio harveyi NH (3)-dependent NAD (+) synthetase CSB-YP417784VEA
CSB-EP417784VEA
CSB-BP417784VEA
CSB-MP417784VEA
CSB-EP417784VEA-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Vibrio harveyi Acyl transferase (luxD) CSB-YP417785VEA
CSB-EP417785VEA
CSB-BP417785VEA
CSB-MP417785VEA
CSB-EP417785VEA-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Vibrio harveyi UPF0176 protein VIBHAR_06657 (VIBHAR_06657) CSB-YP417786VEA
CSB-EP417786VEA
CSB-BP417786VEA
CSB-MP417786VEA
CSB-EP417786VEA-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Vibrio harveyi Probable transcriptional regulatory protein VIBHAR_07036 (VIBHAR_07036) CSB-YP417787VEA
CSB-EP417787VEA
CSB-BP417787VEA
CSB-MP417787VEA
CSB-EP417787VEA-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Francisella tularensis subsp. holarctica D-tyrosyl-tRNA (Tyr) deacylase CSB-YP417788FDV
CSB-EP417788FDV
CSB-BP417788FDV
CSB-MP417788FDV
CSB-EP417788FDV-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Francisella tularensis subsp. holarctica Protein CrcB homolog (crcB), partial CSB-YP417789FDV1
CSB-EP417789FDV1
CSB-BP417789FDV1
CSB-MP417789FDV1
CSB-EP417789FDV1-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Francisella tularensis subsp. holarctica Elongation factor P (efp) CSB-YP417790FDV
CSB-EP417790FDV
CSB-BP417790FDV
CSB-MP417790FDV
CSB-EP417790FDV-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Francisella tularensis subsp. holarctica 30S ribosomal protein S7 (rpsG) CSB-YP417791FDV
CSB-EP417791FDV
CSB-BP417791FDV
CSB-MP417791FDV
CSB-EP417791FDV-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Francisella tularensis subsp. holarctica 30S ribosomal protein S19 (rpsS) CSB-YP417792FDV
CSB-EP417792FDV
CSB-BP417792FDV
CSB-MP417792FDV
CSB-EP417792FDV-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Francisella tularensis subsp. holarctica 30S ribosomal protein S8 (rpsH) CSB-YP417793FDV
CSB-EP417793FDV
CSB-BP417793FDV
CSB-MP417793FDV
CSB-EP417793FDV-B
20μg/100μg/1mg(1mg*1 or 500ug*2)

有用資源

什么是重組蛋白?

重組蛋白是一種可操縱的蛋白質(zhì)形式,可以通過多種方式產(chǎn)生大量蛋白質(zhì)、修改基因序列和制造有用的商業(yè)產(chǎn)品。重組蛋白的技術(shù)資源在重組蛋白的開發(fā)過程中,除了表達(dá)系統(tǒng)之外,還面臨著一系列令人困惑的選擇,如表達(dá)載體的選擇、表達(dá)蛋白的長(zhǎng)度(全長(zhǎng)或部分)、是否帶標(biāo)簽等。在生產(chǎn)重組蛋白時(shí),你必須做出很多決定。如果你選擇的明智,你將獲得高質(zhì)量的重組蛋白,后續(xù)的實(shí)驗(yàn)更有可能成功。但是如果你做了錯(cuò)誤的決定,你可能得不到你所需要的重組蛋白或者重組蛋白的質(zhì)量和純度不符合要求。在這里,來(lái)自CUSABIO的蛋白表達(dá)工程師根據(jù)他們開發(fā)重組蛋白的經(jīng)驗(yàn)總結(jié)出了幾個(gè)有用的提示,可以幫助你做出明智的決策。

第一條:重組蛋白的生產(chǎn),在這篇文章中,我們旨在闡明重組蛋白的定義以及如何生產(chǎn)重組蛋白。

第二條:如何選擇合適的表達(dá)載體?

表達(dá)載體是一種DNA分子,它攜帶特定的基因進(jìn)入宿主細(xì)胞,并利用細(xì)胞的蛋白質(zhì)合成機(jī)制來(lái)產(chǎn)生由該基因編碼的蛋白質(zhì)。表達(dá)載體可使外源基因在宿主細(xì)胞中高效表達(dá),經(jīng)過多年的發(fā)展,表達(dá)載體已成為一種成熟而受歡迎的生物技術(shù)。在重組蛋白生產(chǎn)過程中是一種基本成分。正如標(biāo)題所示,本文主要總結(jié)了幾個(gè)有用的技巧來(lái)選擇合適的表達(dá)載體。

第三條:如何表達(dá)具有生物活性的蛋白質(zhì)?

根據(jù)重組蛋白的不同應(yīng)用,對(duì)其生物活性有不同的要求。但是我們?nèi)绾未_保蛋白質(zhì)的產(chǎn)生具有生物活性呢?本文將圍繞這個(gè)主題,并提供一些解決方案。除了以上文章,我們還收集了一些重組蛋白的常見問題。您可以單擊以下鏈接查看。http://m.cstxtech.com/technology-91.html。此外,我們還為我們的客戶提供重組蛋白表達(dá)服務(wù),您可以點(diǎn)擊這里獲取更多信息。注:如果您對(duì)CUSABIO的蛋白質(zhì)有任何疑問,涉及到蛋白質(zhì)的價(jià)格、交貨、質(zhì)量等,您可以點(diǎn)擊橙色按鈕為我們?cè)诰€留言。

引用資料

Recombinant Severe acute respiratory syndrome coronavirus 2 RNA-dependent RNA polymerase(NSP12) cited in "SARS-CoV-2 hijacks cellular kinase CDK2 to promote viral RNA synthesis". Signal transduction and targeted therapy, 2023

Recombinant Mouse Mixed lineage kinase domain-like protein(Mlkl) cited in "OASL phase condensation induces amyloid-like fibrillation of RIPK3 to promote virus-induced necroptosis". Nature cell biology, 2023

Recombinant Mouse Proto-oncogene c-Fos(Fos) cited in "Dihydroartemisinin imposes positive and negative regulation on Treg and plasma cells via direct interaction and activation of c-Fos". Communications biology, 2023

Recombinant Human Keratin, type I cytoskeletal 18(KRT18) cited in "Calcitonin gene-related peptide ameliorates sepsis-induced intestinal injury by suppressing NLRP3 inflammasome activation". International immunopharmacology, 2023

Recombinant Human Protein Wnt-5a (WNT5A) cited in "ATBF1 is a potential diagnostic marker of histological grade and functions via WNT5A in breast cancer". BMC Cancer, 2022

Read More >>